A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features

A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features

Abstract In acute myeloid leukemia (AML), myelodysplasia‐related changes contribute to a poor prognosis. This retrospective, propensity score‐matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (aged 14‐60 years) from 2014 to 2018, who received eith...

Full description

Bibliographic Details
Main Authors: Fengqi Liu, Hehua Wang, Junru Liu, Zhenhai Zhou, Dong Zheng, Beihui Huang, Chang Su, Waiyi Zou, Duorong Xu, Xiuzhen Tong, Juan Li
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
acute myeloid leukemia
chemotherapy
complete remission
decitabine
induction therapy
MDS features
Online Access:https://doi.org/10.1002/cam4.2418

Internet

https://doi.org/10.1002/cam4.2418

Similar Items